Recently Featured

Fresenius Medical Care Issues Class 4 Medicines Defect Notification for Peritoneal Dialysis Solution

May 29, 2026
Fresenius Medical Care Deutschland GmbH has issued a Class 4 Medicines Defect Notification concerning its balance solution containing 2.3% glucose and 1.25 mmol/l calcium, intended for peritoneal dialysis. The notification highlights a critical error in the Braille printed on the outer label, which may lead to misinterpretation of the product’s usage instructions. This defect is…

Sun recalls US chemotherapy batch, citing glass particle contamination concerns

May 29, 2026
Generics juggernaut Sun Pharma is recalling a specific lot of a chemotherapy drug in the United States due to concerns over glass particle contamination. This action highlights a recurring issue within the pharmaceutical industry, where particulate contamination has increasingly become a focus for regulatory bodies such as the FDA. The recall not only raises questions…

Bora Group Acquires MacroGenics’ CDMO Operations for Up to $127.5 Million

May 29, 2026
Taiwan’s Bora Group has announced its acquisition of the contract development and manufacturing organization (CDMO) operations from Maryland-based MacroGenics for a total consideration of up to $127.5 million. This strategic move reflects Bora’s commitment to expanding its capabilities in the biopharmaceutical manufacturing sector, enhancing its portfolio and operational footprint. The acquisition comes at a time…

Johns Hopkins Study Reveals Mechanisms of Receptor Transport in Neurons via Transcytosis

May 29, 2026
Researchers at Johns Hopkins University have successfully visualized the transport of the nerve growth factor receptor TrkA within neurons through a process known as transcytosis. This imaging study sheds light on how this unconventional mechanism facilitates neuronal function and connectivity in mice, providing critical insights into receptor trafficking that could influence future therapeutic strategies. In…

Ongoing Cases